All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

STARGLO trial of glofitamab: primary endpoint met in R/R DLBCL

Apr 15, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in DLBCL.

Bookmark this article

On April 15, 2024, it was announced that the phase III STARGLO trial (NCT04408638) assessing glofitamab, a CD20 × CD3 T-cell engaging bispecific antibody, plus gemcitabine and oxaliplatin vs rituximab plus gemcitabine and oxaliplatin met its primary endpoint of overall survival. Glofitamab in combination with gemcitabine and oxaliplatin demonstrated a statistically significant improvement in overall survival for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of therapy and were not candidates for autologous stem cell transplant. The safety profile of the combination was consistent with the known safety profiles of the individual treatments.

Glofitamab previously received accelerated approval from the U.S. Food and Drug Administration (FDA) and conditional marketing authorization from the European Commission (EC) for the treatment of patients with R/R DLBCL after two or more lines of systemic therapy.

These encouraging data show that glofitamab in combination with gemcitabine and oxaliplatin has the potential to improve survival outcomes in earlier lines of treatment for patients with R/R DLBCL, who currently have limited options.

  1. Business Wire. Genentech’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in phase III STARGLO Study. Published April 15, 2024. Accessed April 15, 2024.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox